[Ip-health] Statement of Knowledge Ecology International - WHO EB Special session on the draft Thirteenth General Programme of Work
Michael H Davis
m.davis at csuohio.edu
Sun Nov 26 19:21:30 PST 2017
"global norms for funding R&D as a public good."
Why isn't this everyone's first priority?
Sent from my T-Mobile 4G LTE Device
-------- Original message --------
From: Thiru Balasubramaniam <thiru at keionline.org>
Date: 11/22/17 10:39 AM (GMT-05:00)
To: "ip-health at lists.keionline.org" <Ip-health at lists.keionline.org>
Subject: [Ip-health] Statement of Knowledge Ecology International - WHO EB Special session on the draft Thirteenth General Programme of Work
22 November 2017
EB Special session on the draft Thirteenth General Programme of Work
3. Draft Thirteenth General Programme of Work
KEI welcomes the opportunity to comment on the 13th General Programme of
Work anchored upon WHO’s vision of achieving universal health coverage.
The key to achieving universal health coverage is to reduce reliance upon
and eventually abandon the practice of using high prices and patent
monopolies as the incentive to invest in R&D. Delinkage models expand the
role of direct funding of research and subsidies for trial costs, and use
money, rather than monopolies, as the incentive mechanism. Without
delinkage, the WHO will never achieve universal health coverage.
The GPW13 should envision a pathway to evaluate and implement alternative
business models that are consistent with universal access to products,
which means, in practical terms, the progressive implementation of
delinkage of R&D costs from the prices of and incentives to invest in
products, something that is essential to reducing prices without
We commend the WHO’s commitment, expressed in GPW13, to strengthen its role
in providing global public goods. To this end, we request Member States to
provide the WHO with the mandate to explore norms and mechanisms to enhance
the transparency of R&D costs, prices and revenues. We reiterate the call
made by India at the 70th SEARO Regional Committee urging the WHO to lead
negotiations on a global R&D agreement which could provide global norms for
funding R&D as a public good.
While the GPW identifies noncommunicable diseases as a strategic priority,
it demonstrates a clear lack of ambition in relation to access to cancer
medicines. We also note that the document is silent on the barriers posed
by intellectual property rules on access to medicines.
The WHO has a variety of existing commitments under the CEWG and Global
Strategy and Plan of Action on Public Health, Innovation, and Intellectual
Property; this legacy should not be forgotten.
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org
Ip-health mailing list
Ip-health at lists.keionline.org
More information about the Ip-health